ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ELUTIA INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.82+0.02 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $36.05M
- P/E (TTM)
- 0.9
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
53.7%+5.5 pts over 5 years
Operating margin
-218.9%−187.1 pts over 5 years
Net margin
434.2%+485.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -15.0% | -19.8% | -22.0% | – | |
| Gross profit | -1.8% | -17.2% | -20.3% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 127.3% | -574.3% | |
| Return on assets | – | -34.2% | 108.4% | |
| Current ratio | – | 2.23 | 2.22 | |
| Debt to equity | – | 1.46 | – | |
| Net debt to EBITDA | – | 0.93× | – | |
| Interest coverage | – | -2.4× | – | |
| Inventory turnover | – | 2.6× | 2.5× | |
| Capex to revenue | – | 1.5% | 15.3% | |
| Diluted shares | – | 3M | 46M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Elutia generated $126.11M from operations and spent $3.79M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$126.11M
Used
$3.79M
Capital expenditure$3.79M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin434.2%
×Asset turnover0.25×
×Equity multiplier-5.30×
=Return on equity, FY2025-574.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 434.2% | 0.25× | -5.30× | -574.3% |
| FY2024 | -372.9% | 0.36× | -0.94× | 127.1% |
| FY2023 | -152.2% | 0.44× | -2.57× | 172.6% |
| FY2022 | -137.9% | 0.35× | 16.02× | -775.1% |
| FY2021 | -52.4% | 0.63× | 4.37× | -144.6% |
| FY2020 | -51.1% | 0.67× | -3.72× | 127.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$53.38M
- Cash generatingOperating cash flow above zero-$44.81M
- Return on assets improvedROA up on the prior year-124.2% → 147.8%
- Earnings backed by cashOperating cash flow above net income-$44.81M vs $53.38M
- Less leverageLong-term debt to assets fell62.6% → –
- Better liquidityCurrent ratio rose0.69 → 2.22
- No dilutionShare count did not rise29M → 46M
- Gross margin improvedGross margin up on the prior year46.42% → 53.66%
- More efficientAsset turnover rose0.33 → 0.34